5 hours ago

Happy Holidays!

On behalf of all of us here at ATXA Therapeutics, we wish you and yours a very happy and peaceful holiday season and the very best for 2025!

Apr 12

ATXA Therapeutics Founder & CEO Receives 2024 NovaUCD Innovation Award

Professor Therese Kinsella, founder and CEO of ATXA Therapeutics, has been named the recipient of the 2024 NovaUCD Innovation Award....

Dec 21, 2023

ATXA Therapeutics Publishes Results of Phase 1 First-in-Human Study Evaluating the Safety & Tolerability of NTP42 in Healthy Volunteers

ATXA Therapeutics have today published a new paper in Frontiers in Pharmacology detailing results of its lead drug candidate NTP42 in a...

May 5, 2023

ATXA Therapeutics to Participate in Bio€quity Europe 2023

ATXA Therapeutics will be attending the 23rd Bio€quity Europe Conference, due to be held from May 14 – 16, 2023, in Dublin’s Convention...

Apr 28, 2023

ATXA to Present at ATS International Conference 2023

ATXA will present data from a First-in-Human (FIH) Phase I trial of NTP42:KVA4, a novel formulation of its lead clinical candidate NTP42...

Dec 14, 2022

NTP42 Demonstrates Key Cardioprotective Benefits in Newly-published Preclinical Findings

ATXA Therapeutics have today published a new paper detailing results of its lead drug candidate NTP42 in preclinical models of pulmonary...

Oct 19, 2022

ATXA Therapeutics receives Funding through the European Innovation Council Accelerator Programme

ATXA Therapeutics Limited (ATXA) is delighted to announce that it is honoured to receive grant and equity funding through the prestigious...

Aug 23, 2022

ATXA Presentation at ERS International Congress 2022

ATXA presented preclinical efficacy results of its lead drug candidate NTP42 for the treatment of pulmonary arterial hypertension (PAH)...

Sep 14, 2021

European Commission publish article on ATXA's PAH-HOPE project

The EU Commission has published a "Results in Brief" article on ATXA Therapeutics' EU-funded PAH-HOPE project. Entitled "New Hope for...

COMPANY UPDATES